Cipla, insulin

Cipla’s ‘inhaled insulin’ from US’ MannKind Corp adds a ‘layer of convenience’ for those with diabetes
Cipla to introduce Afrezza, an inhaled insulin for diabetes, offering convenience but not advised for lung-related concerns.
Cipla Gets Nod for Insulin Inhalation Powder: Afrezza
Cipla secures CDSCO approval for Afrezza, a rapid-acting insulin delivered through an inhaler, offering a convenient solution for diabetes management in India. The drug is the first and only non-injectable insulin for both type 1 and type 2 diabetes.
Cipla gets CDSCO nod to market insulin inhalation powder for diabetes management
Taken at the beginning of a meal, the medication dissolves rapidly upon oral inhalation into the lungs and delivers insulin quickly to the bloodstream.
Cipla to bring in inhaled insulin Afrezza from US’ MannKind Corporation
Cipla receives approval to market Afrezza, a rapid-acting insulin inhaler, offering a needle-free solution for diabetes management.
CDSCO approves Cipla to distribute, market inhaled insulin in India
Indian regulator Central Drugs Standard Control Organisation (CDSCO) has approved Cipla to exclusively distribute and market inhaled insulin in the country, the drugmaker said on Wednesday.
Cipla gets approval to market Afrezza insulin inhalation powder in India
Drug maker Cipla on Wednesday said it has received approval from the Central Drugs Standard Control Organisation for the distribution and marketing of Afrezza inhalation powder in India.
CDSCO gives nod to Cipla for distribution and marketing of inhaled insulin in India
This is the first and only non- injectable insulin to be developed for patients of both type 1 and type 2 diabetes mellitus.
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
India has the 2nd highest burden of diabetes worldwideCDSCO decision follows existing approvals in the U.S.A. and BrazilMannKind expects to ship
Cipla gets CDSCO nod to launch inhalation insulin
Cipla received approval from CDSCO to distribute and market Afrezza, an inhalable insulin, in India. Developed by MannKind, Afrezza offers a non-injectable alternative for adults with type 1 and type 2 diabetes.
FiercePharma8d
Novo Nordisk slashes prices of additional insulin products but not until 2026
Novo will drop its U.S. list price for its Fiasp by 75% and for Tresiba by 72%, the Danish company said in a release. The new ...
ThePrint on MSN1d
Cipla set to bring Afrezza, 1st inhalable insulin since Exubera, to Indian markets by 2025
Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...
Yahoo Finance9d
Growth Trends in the Insulin Biosimilar Market, Forecast to 2034
For instance, Sanofi stated in January 2024 that a phase 3 clinical trial for individuals with type 2 diabetes will be ...
Taiwan News9d
Rapid Acting Insulin Market is projected to groww with magnificent CAGR 2033 Exclusive Report
However, the reluctance in adoption of rapid acting insulin due to the side effect, such as hypoglycemia, may hinder the growth of the industry. Conversely, untapped market and undiagnosed population ...